Local and regional anesthesia and analgesia appear to be undergoing a renaissance, as judged by attendance at specialty meetings and substantial increase in research activity, as evidenced by growing number of scientific publications. In contrast to general anesthesia, in which the molecular mechanism remains the subject of speculation, the site at which local anesthetic (LA) drugs bind to produce nerve blocks has been cloned and mutated. This chapter focuses on mechanisms of anesthesia and toxicity, especially as knowledge of these mechanisms will assist the clinician in conducting safer and more effective regional anesthesia.
PREHISTORY AND HISTORY
The Incas regarded coca as a gift from the son of the sun God and limited its use to the “upper crust” of society. They recognized and used the medicinal properties of cocaine long before the compound was brought to Europe for its properties to be “discovered.” The Incas sometimes treated persistent headaches with trepanation, and coca was occasionally used to facilitate this procedure. Local anesthesia was accomplished by having the operator chew coca leaves and apply the macerated pulp to the skin and wound edges while using a tumi knife to bore through the bone. By the sixteenth century, having disrupted Incan society, the conquistadors began paying laborers with cocaine paste.
The laborers generally rolled the cocaine leaves into balls (called cocadas), bound together by guano or cornstarch. These cocadas released the free-base cocaine as a consequence of the alkalinity of the guano and of the practice of chewing the cocadas with ash or lime (such alkaline compounds increase pH, favoring the free-base cocaine form over the positively charged hydrochloride salt). This practice probably marks the birth of “free-basing” cocaine and is the historic antecedent of the “rock” or “crack” cocaine so often abused in Western societies. Cocaine was brought back to Vienna by an explorer/physician named Scherzer. In Vienna, the chemist Albert Niemann isolated and crystallized pure cocaine hydrochloride in 1860. The Merck Company distributed batches of this agent to physicians for investigational purposes. Sigmund Freud was the most prominent of these cocaine experimenters. Freud reviewed his experimental work in a monograph devoted to cocaine, Über Coca. Freud and Carl Koller (an ophthalmology trainee) took cocaine orally and noticed that the drug rendered their tongues insensible. Koller and Joseph Gartner began a series of experiments using cocaine to produce topical anesthesia of the conjunctiva.
The birth of local and regional anesthesia dates from 1884, when Koller and Gartner reported their success at producing topical cocaine anesthesia of the eye in the frog, rabbit, dog, and human. The use of local anesthesia quickly spread around the world. The American surgeon William Halsted at Roosevelt Hospital in New York reported using cocaine to produce mandibular nerve block in 1884 and to produce brachial plexus block less than a year later. These blocks were accomplished by surgically exposing the nerves, then injecting them under direct vision. Leonard Corning injected cocaine near the spine of dogs, producing what was likely the first epidural in 1885. Spina anesthesia with cocaine was first accomplished in 1898 by August Bier. Cocaine spinal anesthesia was used to treat cancer pain in 1898. Caudal epidural anesthesia was introduced in 1902 by Sicard and Cathelin. Bier described intravenous regional anesthesia in 1909. In 1911, Hirschel reported the first three percutaneous brachial plexus anesthesias. Fidel Pages reported using epidural anesthesia for abdominal surgery in 1921. Cocaine was soon incorporated into many other products, including the original formulation of Coca-Cola devised by Pemberton in 1886. Wine tonics and other “patent” medicines of the day commonly contained cocaine (Figure 1). This practice ended when cocaine became regulated by the forerunner of the Food and Drug Administration (FDA) in the early 1900s.
Cocaine and all other LAs contain an aromatic ring and an amine at opposite ends of the molecule, separated by a hydrocarbon chain, and either an ester or an amide bond (Figure 2). Cocaine, the archetypical ester, is the only naturally occurring LA. Procaine, the first synthetic ester LA, was introduced in 1904 by Einhorn. The introduction of the amide LA lidocaine in 1948 was transformative. Lidocaine quickly became used for all forms of regional anesthesia. Other amide LAs based on the lidocaine structure (prilocaine, etidocaine) subsequently appeared. A related series of amide LAs based on 2’,6’-pipecoloxylidide was introduced (mepivacaine, bupivacaine, ropivacaine, and levobupivacaine). Ropivacaine and levobupivacaine are the only commercially available single-enantiomer (single-optical-isomer) LAs. Both are S(–)-enantiomers, avoiding the increased cardiac toxicity associated with racemic mixtures and the R(+)-isomers (this is discussed in a subsequent section). All other LAs either exist as racemates or have no asymmetric carbons.
- All LAs contain an aromatic ring and an amine at opposite ends of the molecule, separated by a hydrocarbon chain, and either an ester or an amide bond.
BIOPHYSICS OF VOLTAGE-GATED SODIUM CHANNELS AND LOCAL ANESTHETICS
Studies of the mechanisms of LA action on peripheral nerves are studies of interactions between LAs and voltage-gated Na channels because Na channels contain the LA-binding site. Na channels are integral membrane proteins that initiate and propagate action potentials in axons, dendrites, and muscle tissue; initiate and maintain membrane potential oscillations in specialized heart and brain cells; and shape and filter synaptic inputs. Na channels share structural features with other similar voltage-gated ion channels that exist as tetramers, each with six transmembrane helical segments (eg, voltage-gated Ca and K channels). Na channels contain one larger α-subunit and one or two smaller β-subunits, depending on the species and the tissue of origin. The α-subunit, the site of ion conduction and LA binding, has four homologous domains, each with six α-helical membrane-spanning segments (Figure 3). The external surface of the α-subunit is heavily glycosylated, which serves to orient the channel properly within the plasma membrane (Figure 4). Invertebrates have only one or two Na channel α-subunit genes, and the normal physiologic role of these channels is unclear (animals survive when the channels are not present).
TABLE 1.Voltage-gated Na channel—neural isoforms.
|Nav 1.1||Nav 1.2||Nav 1.3||Nav 1.6||Nav 1.7||Nav 1.8||Nav 1.9|
|Where identified||CNS, DRG||CNS||CNS upregulated, after injury||DRG (large and small), CNS, Ranvier||DRG (large and small)||DRG (small)||DRG (small)|
Source: Adapted with permission from Novakovic SD, Eglen RM, Hunter JC: Regulation of Na+ channel distribution in the nervous system. Trends Neurosci. 2001 Aug;24(8):473-478.
Humans, in contrast, have nine active Na channel α-subunit genes on four chromosomes, with cell-specific expression and localization of gene products.10 The Nav 1.4 gene (by convention, geneticists refer to voltage-gated Na channel isoforms as Nav 1.x) supplies channels to skeletal muscle, and the Nav 1.5 gene supplies channels to cardiac muscle, leaving seven Nav isoforms in neural tissue (Table 1). Defined genes contribute specific Na channel forms to each of the unmyelinated axons, nodes of Ranvier in motor axons, and small dorsal root ganglion nociceptors. Whereas all Na channel α-subunits will bind LAs similarly, their affinity for binding neurotoxins varies. Na channel α- and β-subunit mutations lead to muscle, cardiac, and neural diseases. For example, inherited mutations in Nav 1.5 have been associated with congenital long QT syndrome, Bruguda syndrome, and other conduction system diseases. It has been shown that certain Nav isoforms proliferate in animal models of chronic pain. The existence of specific Nav gene α-subunit products offers the enticing possibility that inhibitors may someday be developed for each specific Nav α-subunit form. Such developments, already underway for some Nav isoforms, could revolutionize the treatment of chronic pain. Blocking of impulses in a nerve fiber requires that a defined length of nerve become inexcitable (to prevent the impulse from “jumping over” the blocked segment). Thus, as the LA concentration increases, it must be applied along a shorter length of nerve to prevent impulse conduction, as is shown in Figure 5. Both normal conduction and the way in which LAs inhibit conduction differ between myelinated and unmyelinated nerve fibers. Conduction in myelinated fibers proceeds in jumps from one Ranvier node to the next, a process termed saltatory conduction. To block impulses in myelinated nerve fibers, it is generally necessary for LAs to inhibit channels in three successive Ranvier nodes (Figure 6). Unmyelinated fibers, lacking the saltatory mechanism, conduct much more slowly than myelinated fibers. Unmyelinated fibers are relatively resistant to LAs, despite their smaller diameter, due to dispersal of Na channels throughout their plasma membranes. These differences among nerve fibers arise during development when Na channels begin to cluster at Ranvier nodes in myelinated axons. Nodal clustering of channels, essential for high-speed signal transmission, is initiated by Schwann cells in the peripheral nervous system and by oligodendrocytes in the central nervous system (CNS). Na channels may exist in at least three native conformations: “resting,” “open,” and “inactivated,” first described by Hodgkin and Huxley. During an action potential, neuronal Na channels open briefly, allowing extracellular Na ions to flow into the cell, depolarizing the plasma membrane. After only a few milliseconds, Na channels inactivate (where upon the Na current ceases). Na channels return to the resting conformation with membrane repolarization. The process by which channels go from conducting to nonconducting forms is termed gating. Gating is assumed to result from movements of dipoles in response to changes in potential. The process by which voltage-gated channels operate likely involves movements of paddle-shaped voltage sensors within the channel’s outer perimeter (Figure 7). The speed of gating processes differs among Nav α-subunit forms: Skeletal muscle and nerve forms gate quicker than cardiac forms.
Anesthesia results when LAs bind Na channels and inhibit the Na permeability that underlies action potentials. Our understanding of LA mechanisms has been refined by several key observations. Taylor confirmed that LAs selectively inhibit Na channels in nerves. Strichartz first observed use-dependent block with LAs, showing the importance of channel opening for LA binding. Use (or frequency) dependence describes how LA inhibition of Na currents increases with repetitive depolarizations (“use”). Repetitive trains of depolarizations increase the likelihood that an LA will encounter an Na channel that is open or inactivated, with both forms having greater LA affinity than do resting channels (Figure 8). Thus, membrane potential influences both Na channel conformation and Na channel affinity for LAs. Use-dependent block appears important for the functioning of LAs as antiarrhythmics and may also underlie the effectiveness of reduced LA concentrations in managing pain. Finally, using site-directed mutagenesis, Ragsdale and Wang localized LA binding to specific amino acids in D4S6 of Nav 1.2 and Nav 1.4. Some LA optical isomers confer greater apparent safety than their opposite enantiomer. For example, under voltage clamp, the R(+)-bupivacaine isomer more potently inhibits cardiac Na currents than the S(–)-bupivacaine (levobupivacaine) isomer (Figure 9). Many other types of chemicals will also bind and inhibit Na channels, including general anesthetics, substance P inhibitors, α2-adrenergic agonists, tricyclic antidepressants, and nerve toxins. Nerve toxins are currently undergoing animal and human testing as possible replacements for LAs.
LOCAL ANESTHETIC PHARMACODYNAMICS
In clinical practice, LAs are typically described by their potency, duration of action, speed of onset, and tendency for differential sensory nerve block. These properties do not sort independently.
Potency and Duration
Nerve-blocking potency of LAs increases with increasing molecular weight and increasing lipid solubility. Larger, more lipophilic LAs permeate nerve membranes more readily and bind Na channels with greater affinity. For example, etidocaine and bupivacaine have greater lipid solubility and potency than lidocaine and mepivacaine, to which they are closely related chemically.
- Nerve-blocking potency of LAs increases with increasing molecular weight and increasing lipid solubility.
More lipid-soluble LAs are relatively water insoluble, highly protein bound in blood, less readily removed by the bloodstream from nerve membranes, and more slowly “washed out” from isolated nerves in vitro. Thus, increased lipid solubility is associated with increased protein binding in blood, increased potency, and longer duration of action. Extent and duration of anesthesia can be correlated with LA content of nerves in animal experiments. In animals, blocks of greater depth and longer duration arise from smaller volumes of more concentrated LA, compared with larger volumes of less-concentrated LA.
Speed of Onset
Many textbooks and review articles assert that the onset of anesthesia in isolated nerves slows with increasing LA lipid solubility and increasing pKa (Table 2). At any pH, the percentage of LA molecules present in the uncharged form, largely responsible for membrane permeability, decreases with increasing pKa.However, of the two LAs with the fastest onset, etidocaine is highly lipid soluble and chloroprocaine has a pKa greater than that of other LAs. Finally, the LA rate of onset is associated with the aqueous diffusion rate, which declines with increasing molecular weight.
TABLE 2.Local anesthetic characteristics that tend to sort together.
Physical and Chemical
- Increasing lipid solubility
- Increased protein binding
Pharmacologic and Toxicologic
- Increasing potency
- Increasing onset time
- Increasing duration of action
- Increasing tendency for severe systemic toxicity
- In general, all tend to sort together
Differential Sensory Nerve Block
Regional anesthesia and pain management would be transformed by a LA that would selectively inhibit pain transmission while leaving other functions intact. However, sensory anesthesia sufficient for skin incision usually cannot be obtained without motor impairment. As was first demonstrated by Gasser and Erlanger in 1929, all LAs will block smaller (diameter) fibers at lower concentrations than are required to block larger fibers of the same type. As a group, unmyelinated fibers are resistant to LAs compared with larger myelinated A-δ fibers. Bupivacaine and ropivacaine are relatively selective for sensory fibers. Bupivacaine produces more rapid onset of sensory than motor block, whereas the closely related chemical mepivacaine demonstrates no differential onset during median nerve blocks (Figure 10). True differential anesthesia may be possible when Nav isoform-selective antagonists become available. Certain Nav isoforms have been found to be prevalent in dorsal root ganglia, and (as previously noted) the relative populations of various Nav isoforms can change in response to various pain states.
Other Factors Influencing Local Anesthetic Activity
Many factors influence the ability of a given LA to produce adequate regional anesthesia, including the dose, site of administration, additives, temperature, and pregnancy. As the LA dose increases, the likelihood of success and the duration of anesthesia increase, while the delay of onset and tendency for differential block decrease. In general, the fastest onset and shortest duration of anesthesia occur with spinal or subcutaneous injections; a slower onset and longer duration are obtained with plexus blocks.
- The effectiveness of a given LA is influenced by the dose, site of administration, additives, temperature, and changes in neural susceptibility, as seen during pregnancy.
Epinephrine is frequently added to LA solutions to cause vasoconstriction and to serve as a marker for intravascular injection. Epinephrine and other α1-agonists increase LA duration largely by prolonging and increasing intraneural concentrations of LAs. Blood flow is decreased only briefly, and the block will persist long after the α1-adrenergic effect on blood flow has dissipated. Other popular LA additions include clonidine, NaHCO3, opioids, dexamethasone, and hyaluronidase. Uncharged local anesthetics have greater apparent potency at basic pH, where an increased fraction of LA molecules is uncharged, than at more acidic pH (Figure 11). Uncharged LA bases diffuse across nerve sheaths and membranes more readily than charged LAs, hastening onset of anesthesia. Some clinical studies showed that the addition of sodium bicarbonate had an inconsistent action during clinical nerve block; however, not all studies demonstrated a faster onset of anesthesia. One might anticipate that bicarbonate would have its greatest effect when added to LA solutions to which epinephrine was added by the manufacturer. Such solutions are more acidic than “plain” (epinephrine-free) LA solutions to increase shelf life. Bicarbonate shortens the duration of lidocaine in animals. Curiously, once LAs gain access to the cytoplasmic side of the Na channel, H+ ions potentiate use-dependent block. Marked prolongation of local anesthesia can be achieved by incorporating LAs into liposomes, as has been done with bupivacaine in the some formulation.
- Pregnancy increases neural susceptibility to LAs.
Pregnant women and pregnant animals demonstrate increased neural susceptibility to LAs. In addition, spread of neuraxial anesthesia likely increases during pregnancy due to decreases in thoracolumbar cerebrospinal fluid volume.
BLOOD CONCENTRATIONS AND PHARMACOKINETICS
Peak LA concentrations vary by the site of injection (Figure 12). With the same LA dose, intercostal blocks consistently produce greater peak LA concentrations than epidural or plexus blocks. As has been recently discussed by others, it makes little sense to speak of “maximal” doses of LAs except in reference to a specific nerve block procedure, since peak blood levels vary widely by block site. In blood, all LAs are partially protein bound, primarily to α1-acid glycoprotein and secondarily to albumin.
Affinity for α1-acid glycoprotein correlates with LA hydrophobicity and decreases with protonation (acidity). Extent of protein binding is influenced by the concentration of α1-acid glyco-protein. Both protein binding and protein concentration decline during pregnancy. During longer-term infusion of LA and LA-opioid combinations, concentrations of LA-binding proteins progressively increase There is considerable first-pass uptake of LAs by the lungs, and animal studies suggest that patients with right-to-left cardiac shunting may be expected to demonstrate LA toxicity after smaller intravenous bolus doses.
- Recommendations on maximal doses of LAs commonly found in pharmacology texts are not terribly useful in the practice of clinical regional anesthesia.
- The serum concentrations of LAs depend on the injection technique, place of injection, and addition of additives to the LA.
- Any recommendation on the maximal safe LA dose can be valid only in reference to a specific nerve block procedure.
Esters undergo rapid hydrolysis in blood, catalyzed by non-specific esterases. Procaine and benzocaine are metabolized to para-aminobenzoic acid (PABA), the species underlying anaphylaxis to these agents. Higher doses of benzocaine, typically for topical anesthesia for endoscopy, can lead to life threatening levels of methemoglobinemia. The amides undergo metabolism in the liver. Lidocaine undergoes oxidative N-deal-kylation (by the cytochromes CYP 1A2 and CYP 3A4 to monoethyl glycine xylidide and glycine xylidide). Bupivacaine, ropivacaine, mepivacaine, and etidocaine also undergo N-dealkylation and hydroxylation. Prilocaine is hydrolyzed to o-toluidine, the agent that causes methemoglobinemia. Prilocaine doses of as little as 400 mg in fit adults may be expected to produce methemoglobinemia concentrations great enough to cause clinical cyanosis. Amide LA clearance is highly dependent on hepatic blood flow, hepatic extraction, and enzyme function; therefore, amide LA clearance is reduced by factors that decrease hepatic blood flow, such as β-adrenergic receptor or H2-receptor blockers, and by heart or liver failure. Disposition of amide LAs is altered in pregnancy due to increased cardiac output, hepatic blood flow, and clearance, as well as the previously mentioned decline in protein binding. Renal failure tends to increase volume of distribution of amide LAs and to increase the accumulation of metabolic by-products of ester and amide LAs. Theoretically, cholinesterase deficiency and cholinesterase inhibitors should increase the risk of systemic toxicity from ester LAs; however, there are no confirmatory clinical reports. Some drugs inhibit various cytochromes responsible for LA metabolism; however, the importance of cytochrome inhibitors varies depending on the specific LA species. β-Blockers and H2-receptor blockers inhibit CYP 2D6, which may contribute to reduced amide LA metabolism. Itraconazole has no effect on hepatic blood flow, but inhibits CYP 3A4 and bupivacaine elimination by 20%–25. Ropivacaine is hydroxylated by CYP 1A2 and metabolized to 2′,6′-pipecoloxylidide by CYP 3A4. Fluvoxamine inhibition of CYP 1A2 reduces ropiva-caine clearance by 70%. On the other hand, coadministration with strong inhibitors of CYP 3A4 (ketoconazole, itraconazole) has only a small effect on ropivacaine clearance.
DIRECT TOXIC SIDE EFFECTS
It is a common, but misguided, assumption that all LA actions, including toxic side effects, arise from interaction with voltage-gated Na channels. There is abundant evidence that LAs will bind many other targets aside from Na channels, including voltage-gated K and Ca channels, KATP channels, enzymes, N-methyl-D-aspartate receptors, β-adrenergic receptors, G-protein-mediated modulation of K and Ca channels, and nicotinic acetylcholine receptors. LA binding to any one or all of these other sites could underlie LA production of spinal or epidural analgesia and could contribute to toxic side effects.
Central Nervous System Side Effects
Local anesthetic CNS toxicity arises from selectively blocking the inhibition of excitatory pathways in the CNS, producing a stereotypical sequence of signs and symptoms as the LA concentration in blood gradually increases (Table 3). With increased LA doses, seizures may arise in the amygdala. With further LA dosing, CNS excitation progresses to CNS depression and eventual respiratory arrest. More potent (at nerve block) LAs produce seizures at lower blood concentrations and at lower doses than less-potent LAs. In animal studies, both metabolic and respiratory acidosis decreased the convulsive dose of lidocaine.
TABLE 3.Progression of signs and symptoms of toxicity as the local anesthetic dose (or concentration) gradually increases.
- Ominous feelings
- Circumoral numbness
- Myoclonic jerks
- Cardiovascular collapse
In laboratory experiments, most LAs will not produce cardiovascular (CV) toxicity until the blood concentration exceeds three times that necessary to produce seizures; however, there are clinical reports of simultaneous CNS and CV toxicity with bupivacaine (Table 4). In dogs, supraconvulsant doses of bupivacaine more commonly produce arrhythmias than supraconvulsant doses of ropivacaine and lidocaine. LAs produce CV signs of CNS excitation (increased heart rate, arterial blood pressure, and cardiac output) at lower concentrations than those associated with cardiac depression. Hypocapnia reduces ropivacaine-induced changes in ST segments and left ventricular contractility.
- In laboratory experiments, most LAs will not produce CV toxicity until the blood concentration exceeds three times that necessary to produce seizures.
TABLE 4.Convulsive versus lethal doses of local anesthetics in dogs.
|Dose producing convulsions in all animals (mg/kg)||22||5||4|
|Dose producing lethality in all animals (mg/kg)||76||20||27|
Local anesthetics bind and inhibit cardiac Na channels (Nav 1.5 isoform). Bupivacaine binds more avidly and longer than lidocaine to cardiac Na channels. As previously noted, certain R(+) optical isomers bind cardiac Na channels more avidly than S(–) optical isomers. These laboratory observations led to the clinical development of levobupivacaine and ropivacaine. Local anesthetics inhibit conduction in the heart with the same rank order of potency as for nerve block. Local anesthetics produce dose-dependent myocardial depression, possibly from interference with Ca signaling mech-anisms within cardiac muscle. These anesthetics bind and inhibit cardiac voltage-gated Ca and K channels at concentrations greater than those at which binding to Na channels is maximal. The LAs bind β-adrenergic receptors and inhibit epinephrine-stimulated cyclic adenosine monophosphate (AMP) formation. In rats, the rank order for cardiac toxicity appears to be bupivacaine > levobupivacaine > ropivacaine. In dogs, lidocaine was the least potent, and bupivacaine and levobupivacaine were more potent than ropivacaine at inhibiting left ventricular function as assessed by echocardiography (Table 5). In dogs, both programmed electrical stimulation and epinephrine resuscitation elicited more arrhythmias after bupivacaine and levobupivacaine than after lidocaine or ropivacaine administration. The mechanism by which CV toxicity is produced may depend on which LA has been administered. When LAs were given to the point of extreme hypotension, dogs receiving lidocaine could be resuscitated but required continuing infusion of epinephrine to counteract LA-induced myocardial depression. Conversely, many dogs receiving bupivacaine or levobupivacaine to the point of extreme hypotension could not be resuscitated. After bupivacaine, levobupivacaine, or ropivacaine, dogs that could be defibrillated often required no additional therapy. Similarly, in pigs, comparing lidocaine with bupivacaine, the ratio of potency for myocardial depression was 1:4, whereas it was 1:16 for arrhythmogenesis. The LAs produce dilation of vascular smooth muscle at clinical concentrations. Cocaine is the only LA that consistently produces local vasoconstriction.
- True immunologic reactions to LAs are rare.
- True anaphylaxis appears more common with ester LAs that are metabolized directly to PABA than other LAs.
- Accidental intravenous injections of LAs are sometimes misdiagnosed as allergic reactions.
- Some patients may react to preservatives, such as meth-ylparaben, included with LAs.
True immunologic reactions to LAs are rare. Accidental intravenous injections of LAs are sometimes misdiagnosed as allergic reactions. True anaphylaxis appears more common with ester LAs that are metabolized directly to PABA than to other LAs. Some patients may react to preservatives, such as methyl-paraben, included with LAs. Several studies have shown that patients referred for evaluation of apparent LA allergy, even after exhibiting signs or symptoms of anaphylaxis, almost never demonstrate true allergy to the LA that was administered. On the other hand, LA skin testing has an excellent negative predictive value. In other words, 97% of patients who fail to respond to LA skin testing will also not have an allergic reaction to the LA in a clinical setting.
TABLE 5.Efects of local anesthetics on indices of myocardial function measured in dogs.
|Local Anesthetic||LVEDP (EC50 for 125% base) (mcg/mL)||dP/dtmax (EC50 for 65% base) (mcg/mL)||%FS (EC50 for 65% base) (mcg/mL)|
|Bupivacaine||2.2 (1.2–4.4)||2.3 (1.7–3.1)||2.1 (1.47–3.08)|
|Levobupivacaine||1.7 (0.9–3.1)||2.4 (1.9–3.1)||1.3 (0.9–1.8)|
|Ropivacaine||4.0 (2.1–7.5)a/sup>||4.0 (3.1–5.2)b||3.0 (2.1–4.2)a/sup>|
|Lidocaine||6.8 (3.0–15.4)c||8.0 (5.7–11.0)d||5.5 (3.5–8.7)d|
During the 1980s, 2-chloroprocaine (at that time formulated with sodium metabisulfite at a relatively acidic pH) occasion-ally produced cauda equina syndrome following accidental large-dose intrathecal injection during attempted epidural administration. Whether the “toxin” is 2-chloroprocaine or sodium metabisulfite remains unsettled: 2-chloroprocaine is now being tested as a substitute for lidocaine in human spinal anesthesia, and a series of publications suggest that it may be safe and effective. At the same time, other investigators have linked neurotoxic reactions in animals to large doses of 2-chlo-roprocaine rather than to metabisulfite. There is also contro-versy about transient neurologic symptoms and persistent sacral deficits after lidocaine spinal anesthesia. The reports and the controversy have persuaded many physicians to abandon lidocaine spinal anesthesia. Unlike other spinal LA solutions, lido-caine 5% permanently interrupts conduction when applied to isolated nerves or to isolated neurons. This may be the result of lidocaine-induced increases in intracellular calcium and does not appear to involve Na channel blockade. While it is impossible to “prove safety,” multiple studies suggest that chloroprocaine or mepivacaine can be substituted for lidocaine for brief spinal anesthesias.
Treatment of Local Anesthetic Toxicity
Treatment of adverse LA reactions depends on their severity. Minor reactions can be allowed to terminate spontaneously. Seizures induced by LAs should be managed by maintaining a patent airway and by providing oxygen. Seizures may be ter-minated with intravenous midazolam (0.05–0.10 mg/kg) or propofol (0.5–1.5 mg/kg) or a paralytic dose of succinylcho-line (0.5–1 mg/kg), followed by ventilation with bag and mask (or tracheal intubation). LA CV depression manifested by moderate hypotension, may be treated by infusion of intravenous fluids and vasopressors (phenylephrine 0.5–5 μg/kg/min, norepinephrine 0.02–0.2 μg/kg/min, or vasopressin 40 μg IV). If myocardial failure is present, epinephrine (1–5 μg/kg IV bolus) may be required. When toxicity progresses to cardiac arrest, the guidelines for treatment of LA toxicity as developed by the American Society of Regional Anesthesia and Pain Medicine (ASRA) are reasonable, and certainly preferable to the chaotic resuscitation schemes identified in a national survey prior to publication of the guideline. It makes sense that amiodarone be substituted for lidocaine and, based on multi-ple animal experiments, that smaller, incremental doses of epinephrine be used initially rather than 1-mg boluses. Animal experiments and clinical reports demonstrate the remarkable ability of lipid infusion to resuscitate from bupivacaine-induced cardiac arrest (Figure 13).Given the nearly nontoxic status of lipid infusion, one cannot make a convincing argument to withhold this therapy from a patient requiring resuscitation from LA intoxication. With unresponsive bupivacaine cardiac toxicity cardiopulmonary bypass should be considered. It appears that the threat from severe local anesthetic systemic toxicity may be on the decline, whether from better treatment or from changes in techniques. A minority would argue that the risk was overstated from the start, at least in experienced hands. Many practitioners believe that ultrasound guidance during peripheral nerve blocks has led to safer practices and less risk. While this view remains controversial, there are studies that support this belief.
After more than a century of use in Western medicine, LAs remain important tools for the twenty-first-century physician. Peripheral nerve blocks are almost certainly the result of LA inhibition of voltage-gated Na channels in neuronal membranes. The mechanisms of spinal and epidural anesthesia remain incompletely defined. The appropriate and safe dose of LAs varies with specific nerve block procedure. The mechanisms by which differing LAs produce CV toxicity likely vary: The more potent agents (eg, bupivacaine) may produce arrhythmias through a Na channel action, whereas the less-potent agents (eg, lidocaine) may produce myocardial depression through other pathways. Fears about LA systemic toxicity have abated with safer LAs, safer regional anesthesia practices, and improved treatments. There is renewed effort to produce clinically applicable delayed-release local anesthetic formulations to extend the duration of the currently available LAs.
- Vandam LD: Some aspects of the history of local anesthesia. In Strichartz GR (ed): Local Anesthetics: Handbook of Experimental Pharmacology. Springer-Verlag, 1987, pp 1–19.
- Calatayud J, Gonzalez A: History of the development and evolution of local anesthesia since the coca leaf. Anesthesiology 2003;98:1503–1508.
- Strichartz GR: Local Anesthetics: Handbook of Experimental Pharmacology. Springer-Verlag, 1987.
- de Jong RH: Local Anesthetics. Mosby-Year Book, 1994.
- Keys TE: The History of Surgical Anesthesia. Wood Library, Museum of Anesthesiology, 1996.
- Butterworth JF IV, Strichartz GR: Molecular mechanisms of local anesthesia: A review. Anesthesiology 1990;72:711–734.
- Tetzlaff J: Clinical Pharmacology of Local Anesthetics. Butterworth-Heinemann, 2000.
- Ahern CA, Payandeh J, Bosmans F, Chanda B. The hitchhiker’s guide to the voltage-gated sodium channel galaxy. J Gen Physiol. 2016;147:1–24.
- de Lera Ruiz M, Kraus RL. Voltage-Gated Sodium Channels: Structure, Function, Pharmacology, and Clinical Indications. J Med Chem. 2015;58:7093–7118.
- Lopreato GF, Lu Y, Southwell A, et al: Evolution and divergence of sodium channel genes in vertebrates. Proc Natl Acad Sci U S A 2001; 98:7588–7592.
- Savio-Galmiberti E. Gollob MH, Darbar D: Voltage-gated sodium channels: Biophysics, pharmacology, and related channelopathies. Front Pharmacol 2012;3:1–19
- Chen-Izu Y, Shaw RM, Pitt GS, et al. Na+ channel function, regulation, structure, trafficking and sequestration. J Physiol. 2015;593:1347–1360
- Hille B: Ionic Channels of Excitable Membranes, 3rd ed. Sinauer, 2001.
- Jiang Y, Lee A, Chen J, et al: X-ray structure of a voltage-dependent K+ channel. Nature 2003;423:33–41.
- Freites JA, Tobias DJ. Voltage Sensing in Membranes: From Macroscopic Currents to Molecular Motions. J Membr Biol. 2015;248:419–430.
- Taylor RE. Effect of procaine on electrical properties of squid axon membrane. Am J Physiol 1959;196:1070–1078.
- Strichartz GR. The inhibition of sodium currents in myelinated nerve by quaternary derivatives of lidocaine. J Gen Physiol. 1973;62:37–57.
- Ragsdale DS, McPhee JC, Scheuer T, et al: Molecular determinants of state-dependent block of Na+ channels by local anesthetics. Science 1994;265:1724–1728.
- Wang GK, Quan C, Wang S: A common local anesthetic receptor for benzocaine and etidocaine in voltage-gated mu1 Na+ channels. Pflugers Arch 1998;435:293–302.
- Sudoh Y, Cahoon EE, Gerner P, et al: Tricyclic antidepressants as long-acting local anesthetics. Pain 2003;103:49–55.
- Kohane DS, Lu NT, Gokgol-Kline AC, et al: The local anesthetic properties and toxicity of saxitonin homologues for rat sciatic nerve block in vivo. Reg Anesth Pain Med 2000;25:52–59.
- Butterworth JF IV, Strichartz GR: The alpha 2-adrenergic agonists clonidine and guanfacine produce tonic and phasic block of conduction in rat sciatic nerve fibers. Anesth Analg 1993;76:295–301.
- Sanchez V, Arthur GR, Strichartz GR: Fundamental properties of local anesthetics. I. The dependence of lidocaine’s ionization and octanol:buffer partitioning on solvent and temperature. Anesth Analg 1987;66: 159–165.
- Strichartz GR, Sanchez V, Arthur GR, et al: Fundamental properties of local anesthetics. II. Measured octanol:buffer partition coefficients and pKa values of clinically used drugs. Anesth Analg 1990;71:158–170.
- Popitz-Bergez FA, Leeson S, Strichartz GR, et al: Relation between functional deficit and intraneural local anesthetic during peripheral nerve block. A study in the rat sciatic nerve. Anesthesiology 1995;83:583–592.
- Sinnott CJ, Cogswell LP III, Johnson A, et al: On the mechanism by which epinephrine potentiates lidocaine’s peripheral nerve block. Anesthesiology 2003;98:181–188.
- Nakamura T, Popitz-Bergez F, Birknes J, et al: The critical role of concentration for lidocaine block of peripheral nerve in vivo: Studies of function and drug uptake in the rat. Anesthesiology 2003;99: 1189–1197.
- Brouneus F, Karami K, Beronius P, et al: Diffusive transport properties of some local anesthetics applicable for iontophoretic formulation of the drugs. Int J Pharm 2001;218:57–62.
- Gissen AJ, Covino BG, Gregus J: Differential sensitivities of mammalian nerve fibers to local anesthetic agents. Anesthesiology 1980;53:467–474.
- Raymond SA, Gissen AJ: Mechanisms of differential nerve block. In Strichartz GR (ed): Handbook of Experimental Pharmacology: Local Anesthetics. Springer-Verlag, 1987, pp 95–164.
- Butterworth J, Ririe DG, Thompson RB, et al: Differential onset of median nerve block: Randomized, double-blind comparison of mepivacaine and bupivacaine in healthy volunteers. Br J Anaesth 1998; 81:515–521.
- Novakovic SD, Eglen RM, Hunter JC: Regulation of Na+ channel distribution in the nervous system. Trends Neurosci 2001;24:473–478.
- Covino BG, Vasallo HG: Local Anesthetics. Grune & Stratton, 1976.
- Kohane DS, Lu NT, Cairns BE, et al: Effects of adrenergic agonists and antagonists on tetrodotoxin-induced nerve block. Reg Anesth Pain Med 2001;26:239–245.
- Butterworth JF IV, Lief PA, Strichartz GR: The pH-dependent local anesthetic activity of diethylaminoethanol, a procaine metabolite. Anesthesiology 1988;68:501–506.
- Fagraeus L, Urban BJ, Bromage PR: Spread of epidural analgesia in early pregnancy. Anesthesiology 1983;58:184–187.
- Butterworth JF IV, Walker FO, Lysak SZ: Pregnancy increases median nerve susceptibility to lidocaine. Anesthesiology 1990;72:962–965.
- Popitz-Bergez FA, Leeson S, Thalhammer JG, et al: Intraneural lidocaine uptake compared with analgesic differences between pregnant and nonpregnant rats. Reg Anesth 1997;22:363–371.
- Scott DB, Jebson PJ, Braid DP, et al: Factors affecting plasma levels of lignocaine and prilocaine. Br J Anaesth 1972;44:1040–1049.
- Rosenberg PH, Veering BTh, Urmey WF: Maximum recommended doses of local anesthetics: A multifactorial concept. Reg Anesth Pain Med 2004;29:564–575.
- Taheri S, Cogswell LP III, Gent A, et al: Hydrophobic and ionic factors in the binding of local anesthetics to the major variant of human alpha1-acid glycoprotein. J Pharmacol Exp Ther 2003;304:71–80.
- Fragneto RY, Bader AM, Rosinia F, et al: Measurements of protein binding of lidocaine throughout pregnancy. Anesth Analg 1994;79: 295–297.
- Thomas JM, Schug SA: Recent advances in the pharmacokinetics of local anaesthetics. Long-acting amide enantiomers and continuous infusions. Clin Pharmacokinet 1999;36:67–83.
- Rothstein P, Arthur GR, Feldman HS, et al: Bupivacaine for intercostal nerve blocks in children: Blood concentrations and pharmacokinetics. Anesth Analg 1986;65:625–632.
- Bokesch PM, Castaneda AR, Ziemer G, et al: The influence of a right-to-left cardiac shunt on lidocaine pharmacokinetics. Anesthesiology 1987; 67:739–744.
- Palkama VJ, Neuvonen PJ, Olkkola KT: Effect of itraconazole on the pharmacokinetics of bupivacaine enantiomers in healthy volunteers. Br J Anaesth 1999;83:659–661.
- Oda Y, Furuichi K, Tanaka K, et al: Metabolism of a new local anesthetic, ropivacaine, by human hepatic cytochrome P450. Anesthesiology 1995; 82:214–220.
- Ekstrom G, Gunnarsson UB: Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes. Drug Metab Dispos 1996;24:955–961.
- Hirota K, Browne T, Appadu BL, et al: Do local anaesthetics interact with dihydropyridine binding sites on neuronal L-type Ca2+ channels? Br J Anaesth 1997;78:185–188.
- Olschewski A, Olschewski H, Brau ME, et al: Effect of bupivacaine on ATP-dependent potassium channels in rat cardiomyocytes. Br J Anaesth 1999;82:435–438.
- Sugimoto M, Uchida I, Fukami S, et al: The alpha and gamma subunit-dependent effects of local anesthetics on recombinant GABA(A) receptors. Eur J Pharmacol 2000;401:329–337.
- Englesson S, Grevsten S: The influence of acid–base changes on central nervous system toxicity of local anaesthetic agents. II. Acta Anaesthesiol Scand 1974;18:88–103.
- Feldman HS, Arthur GR, Covino BG: Comparative systemic toxicity of convulsant and supraconvulsant doses of intravenous ropivacaine, bupivacaine, and lidocaine in the conscious dog. Anesth Analg 1989;69: 794–801.
- Porter JM, Markos F, Snow HM, et al: Effects of respiratory and metabolic pH changes and hypoxia on ropivacaine-induced cardiotoxicity in dogs. Br J Anaesth 2000;84:92–94.
- Chernoff DM: Kinetic analysis of phasic inhibition of neuronal sodium currents by lidocaine and bupivacaine. Biophys J 1990;58:53–68.
- Feldman HS, Covino BM, Sage DJ: Direct chronotropic and inotropic effects of local anesthetic agents in isolated guinea pig atria. Reg Anesth 1982;7:149–156.
- Reiz S, Nath S: Cardiotoxicity of local anaesthetic agents. Br J Anaesth 1986;58:736–746.
- McCaslin PP, Butterworth J: Bupivacaine suppresses [Ca(2+)](i) oscillations in neonatal rat cardiomyocytes with increased extracellular K+ and is reversed with increased extracellular Mg(2+). Anesth Analg 2000;91:82–88.
- Butterworth JF IV, Brownlow RC, Leith JP, et al: Bupivacaine inhibits cyclic-3′,5′-adenosine monophosphate production. A possible contributing factor to cardiovascular toxicity. Anesthesiology 1993;79:88–95.
- Butterworth J, James RL, Grimes J: Structure-affinity relationships and stereospecificity of several homologous series of local anesthetics for the beta2-adrenergic receptor. Anesth Analg 1997;85:336–342.
- Ohmura S, Kawada M, Ohta T, et al: Systemic toxicity and resuscitation in bupivacaine-, levobupivacaine-, or ropivacaine-infused rats. Anesth Analg 2001;93:743–748.
- Dony P, Dewinde V, Vanderick B, et al: The comparative toxicity of ropivacaine and bupivacaine at equipotent doses in rats. Anesth Analg 2000;91:1489–1492.
- Chang DH, Ladd LA, Copeland S, et al: Direct cardiac effects of intracoronary bupivacaine, levobupivacaine and ropivacaine in the sheep. Br J Pharmacol 2001;132:649–658.
- Groban L, Deal DD, Vernon JC, et al: Ventricular arrhythmias with or without programmed electrical stimulation after incremental overdosage with lidocaine, bupivacaine, levobupivacaine, and ropivacaine. Anesth Analg 2000;91:1103–1111.
- Groban L, Deal DD, Vernon JC, et al: Cardiac resuscitation after incremental overdosage with lidocaine, bupivacaine, levobupivacaine, and ropivacaine in anesthetized dogs. Anesth Analg 2001;92:37–43.
- Groban L, Deal DD, Vernon JC, et al: Does local anesthetic stereoselectivity or structure predict myocardial depression in anesthetized canines? Reg Anesth Pain Med 2002;27:460–468.
- Nath S, Haggmark S, Johansson G, et al: Differential depressant and electrophysiologic cardiotoxicity of local anesthetics: An experimental study with special reference to lidocaine and bupivacaine. Anesth Analg 1986;65:1263–1270.
- Carpenter RL, Kopacz DJ, Mackey DC: Accuracy of laser Doppler capillary flow measurements for predicting blood loss from skin incisions in pigs. Anesth Analg 1989;68:308–311.
- deShazo RD, Nelson HS: An approach to the patient with a history of local anesthetic hypersensitivity: Experience with 90 patients. J Allergy Clin Immunol 1979;63:387–394.
- Berkun Y, Ben-Zvi A, Levy Y, et al: Evaluation of adverse reactions to local anesthetics: Experience with 236 patients. Ann Allergy Asthma Immunol 2003;91:342–345.
- Gissen AJ, Datta S, Lambert D: The chloroprocaine controversy. I. A hypothesis to explain the neural complications of chloroprocaine epidural. Reg Anesth 1984;9:124–134.
- Gissen AJ, Datta S, Lambert D: The chloroprocaine controversy. II. Is chloroprocaine neurotoxic? Reg Anesth 1984;9:135–145.
- Winnie AP, Nader AM: Santayana’s prophecy fulfilled. Reg Anesth Pain Med 2001;26:558–564.
- Kouri ME, Kopacz DJ: Spinal 2-chloroprocaine: A comparison with lidocaine in volunteers. Anesth Analg 2004;98:75–80.
- Taniguchi M, Bollen AW, Drasner K: Sodium bisulfite: Scapegoat for chloroprocaine neurotoxicity? Anesthesiology 2004;100:85–91.
- Lambert LA, Lambert DH, Strichartz GR: Irreversible conduction block in isolated nerve by high concentrations of local anesthetics. Anesthesiology 1994;80:1082–1093.
- Gold MS, Reichling DB, Hampl KF, et al: Lidocaine toxicity in primary afferent neurons from the rat. J Pharmacol Exp Ther 1998;285:413–421.
- Neal JM, Bernards CM, Butterworth JF 4th, et al. ASRA practice advisory on local anesthetic systemic toxicity. Reg Anesth Pain Med. 2010;35: 152–61
- Corcoran W, Butterworth J, Weller RS, et al. Local anesthetic-induced cardiac toxicity: a survey of contemporary practice strategies among academic anesthesiology departments. Anesth Analg. 2006;103:1322–6
- El-Boghdadly K, Chin KJ. Local anesthetic systemic toxicity: Continuing Professional Development. Can J Anaesth. 2016;63:330–349
- Krismer AC, Hogan QH, Wenzel V, et al: The efficacy of epinephrine or vasopressin for resuscitation during epidural anesthesia. Anesth Analg 2001;93:734–742.
- Mayr VD, Raedler C, Wenzel V, et al: A comparison of epinephrine and vasopressin in a porcine model of cardiac arrest after rapid intravenous injection of bupivacaine. Anesth Analg 2004;98:1426–1431.
- Weinberg GL, VadeBoncouer T, Ramaraju GA, et al: Pretreatment or resuscitation with a lipid infusion shifts the dose-response to bupivacaine-induced asystole in rats. Anesthesiology 1998;88:1071–1075.
- Weinberg G, Ripper R, Feinstein DL, et al: Lipid emulsion infusion rescues dogs from bupivacaine-induced cardiac toxicity. Reg Anesth Pain Med 2003;28:198–202.
- Fettiplace MR, Weinberg G. Past, Present, and Future of Lipid Resuscitation Therapy. JPEN J Parenter Enteral Nutr. 2015;39(1 Suppl): 72S-83S.
- Soltesz EG, van Pelt F, Byrne JG: Emergent cardiopulmonary bypass for bupivacaine cardiotoxicity. J Cardiothorac Vasc Anesth 2003;17: 357–358.
- Vasques F, Behr AU, Weinberg G, et al. A Review of Local Anesthetic Systemic Toxicity Cases Since Publication of the American Society of Regional Anesthesia Recommendations: To Whom It May Concern. Reg Anesth Pain Med. 2015;40:698–705.
- Liu SS, Ortolan S, Sandoval MV, Curren J, Fields KG, Memtsoudis SG, YaDeau JT. Cardiac Arrest and Seizures Caused by Local Anesthetic Systemic Toxicity After Peripheral Nerve Blocks: Should We Still Fear the Reaper? Reg Anesth Pain Med. 2016;4:5–21.
- Barrington MJ, Kluger R. Ultrasound guidance reduces the risk of local anesthetic systemic toxicity following peripheral nerve blockade. Reg Anesth Pain Med. 2013;38:289–299.
- Neal JM, Brull R, Horn JL, et al. The Second American Society of Regional Anesthesia and Pain Medicine Evidence-Based Medicine Assessment of Ultrasound-Guided Regional Anesthesia: Executive Summary. Reg Anesth Pain Med. 2016;41:181–194